Brief: Corbus Announces Enrollment Completion Of Dose Escalation Stage Of Phase 1 Clinical Trial Of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
16/10/2024 13:05
Oct 16 (Reuters) - Corbus Pharmaceuticals Holdings Inc
CRBP.O :
* CORBUS ANNOUNCES ENROLLMENT COMPLETION OF DOSE ESCALATION
STAGE
OF PHASE 1 CLINICAL TRIAL OF ITS NEXT GENERATION NECTIN-4
TARGETING ADC (CRB-701)
* CORBUS PHARMACEUTICALS HOLDINGS INC - FIRST DATA FROM DOSE
ESCALATION EXPECTED IN Q1 2025
Source text for Eikon: ID:nGNX83SFXG
Further company coverage: CRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study